Drugs / BI 1820237
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06352424 | Apr 2024 → Feb 2025 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05751226 | Apr 2023 → Aug 2024 | obesity disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT04903509 | Jun 2021 → Aug 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-05-17 | Gubra A/S | Results Phase 1 trial results from a novel long acting NPY2-receptor agonist in partnership between Gubra A/S and Boehringer Ingelheim presented today at the European Congress on Obesity, ECO 2023 gubra.dk ↗
The results show no unexpected safety or tolerability concerns with single doses of BI 1820237 with and without liraglutide. |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1820237 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06352424 ↗ |
| Route | Subcutaneous | “Single Rising Subcutaneous Doses of BI 1820237 Alone” NCT04903509 ↗ |